FDA Clearance Sends Soliton Stock Surging

Sentiment surrounding the equity is optimistic

Managing Editor
Mar 11, 2020 at 9:56 AM
facebook twitter linkedin

Shares of Soliton Inc (NASDAQ:SOLY) are surging 7% at $11.40 this morning, higher after the medical device company received 510(k) Premarket Notification clearance at the Food and Drug Administration (FDA) for its Generation II Rapid Acoustic Pulse (RAP) device. The tattoo removal device is similar to its generation I version, but is more catered to the ease of use in a physician's office. 

SOLY has been a relatively steady presence on the charts since mid-2019, contained by the $10- $15 region. However, the equity remains 63% off its late-May record high and is teetering along its year-to-date breakeven mark.

While analysts have yet to chime in on this morning's breakthrough, heading into today the lone brokerage in coverage appeared optimistic. This is per the "buy" rating and average 12-month price target of $22, which is 91% above current trading levels.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners